Find a trial

PACT COVID-19 Update

Many pulmonary fibrosis trials have been suspended whilst respiratory health professionals were called to the frontline of the COVID-19 response. We thank all those who have and continue to work on the frontline.

PACT is pleased to update that due to the improved clinical situation of COVID-19 in Australasia some trials are beginning to recommence. Some sites are starting to accept new trial enrolments. For everyone’s safety, extraordinary measures continue to be in place for patients in trials.

Please continue to check our website for trial updates, we hope to be able to reopen trial enquiries soon. Alternatively, become a member to stay up to date.

Become a member

Deciding to be part of a clinical trial is a very personal decision. People eligible to participate in a clinical trial are limited to a group with very specific characteristics. Please see below clinical trials that are currently recruiting in Australasia. If you are interested in any of the listed trials please register your interest by clicking here. You will then be able to enter your contact details which will then be forwarded to the PACT coordinator. If you are interested in participating in a trial your information may be passed onto a local clinical trials coordinator.

Recruiting Trials

Trial	Title	Status	More Information
Isabela 1&2	A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis	Recruiting	Trial Summary Study ID: NCT0371l-162 Study ID NCT03733444
PFOX	PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial	Recruiting	Trial Summary Study ID: NCT03737409
HIIT	High intensity interval training in fibrotic interstitial lung disease	Recruiting	Trial Summary Study Id: NCT03800914
GRIPF	Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)	Recruiting	Trial Summary Not Applicable
HHF-ILD	Handheld fan for breathlessness in interstitial lung disease	Recruiting	Trial Summary Study ID: ACTRN12618001949279

Trials in Follow Up

Trial	Title	Status	More Information
ATLAS	A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis	Closed to recruitment	Trial Summary Study Id: ACTRN12618001838202
Trail1	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)	Closed to recruitment	Trial Summary Study ID: NCT02808871

Completed Trials

Trial	Title	Status	More Information
COLDICE	Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE	Study completed	Trial Summary Study Id: ACTRN12615000718549
SPIRIT	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Study completed	Trial Summary ClinicalTrials.gov Study ID: NCT03573505

Discontinued Trials

Trial	Title	Status	More Information
SCENIC	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Discontinued The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.	Trial Summary Study ID: NCT03864328